AI-Discovered Drug Shows Potential to Slow Aging in Clinical Study, Biotech Says
Six proteomic aging clocks and 42 trial participants showed rentosertib reversed predicted biological age while lung function improved dose-dependently, Insilico said.
- Insilico Medicine announced in Nature Biotechnology that rentosertib, an AI-discovered drug candidate, reversed predicted biological age in patients with idiopathic pulmonary fibrosis.
- Using its generative AI platform, Insilico identified TNIK as a target relevant to both aging and fibrosis, designing rentosertib to suppress senescence drivers and modulate accelerated aging pathways.
- Analyzing 12-week proteomic data from 42 patients, researchers applied six independently developed aging clocks; all six unanimously indicated rentosertib reduced predicted biological age versus placebo.
- On Tuesday, September 8, 2026, CEO Alex Zhavoronkov will present findings at the Nature conference in Paris, establishing a proof-of-concept framework for integrating aging biomarkers into standard clinical trials.
- Insilico reported total revenue of approximately $106 million in the first half of 2026, achieving its first profitable half-year since listing, with major collaboration contracts exceeding $11 billion.
16 Articles
16 Articles
Insilico AI-Developed Drug Candidate Shows Anti-Aging Potential in New Study
Tech-bio company Insilico said trial data for an experimental drug to treat an age-related lung disease suggests it could have anti-aging properties, boosting hopes for other emerging therapies discovered with artificial intelligence.
AI-designed drug candidate reverses biological age in clinical study
Insilico Medicine ("Insilico"), a clinical-stage company focused on generative AI-driven drug discovery and development, today announced the publication of a new study conducted in collaboration with an international team of scientists from Harvard Medical School, Stanford University, The Broad Institute, RWTH Aachen University, Peking University and Westlake University.
The experimental Rent-Sertib drug developed with I.E. showed a decline in the biological age of patients.
PR Newswire
The AI JournalInsilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks
First-in-Class Evaluation of an AI-Driven Candidate: This is the first de-novo drug designed with generative AI for a de-novo target discovered using AI and...
Coverage Details
Bias Distribution
- 87% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
